BPC June 21 update

Valneva VALN PFE Announce a $95m lyme disease vaccine deal; Minerva NERV Trades post 1-8 reverse split

Pre-Market Updates

Yesterday's BIOrdle ticker was PSTI. Pluristem Therapeutics Inc. (NASDAQ: PSTI) a clinical biotechnology company developing cell therapies. Pluristem has a catalyst planned for the 3Q of 2022 for its Phase 3 trial of PLX-PAD to treat muscle injury following hip fracture. Shares closed Friday up 2% at $1.21.

__________________________

Pfizer Inc (NYSE: PFE) announced a collaborative agreement with Valneva SE (NASDAQ: VALN) to develop the lyme disease vaccine candidate, VLA15. Pfizer will invest €90.5 million ($95 million) for an 8.1% stake in Valneva at €9.49 per share.

ACADIA Pharmaceuticals (NASDAQ: ACAD) tumbled during the pre-market as shares were unhalted following the Advisory Committee recommendation against approval for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announced that it will discontinue its Phase 3 trial of Larazotide to treat celiac disease after the interim analysis reported that the additional number of patients needed to determine a significant clinical outcome between placebo and larazotide is too large to support trial continuation.

Minerva Neurosciences, Inc. (NASDAQ: NERV) shares commenced trading after its 1-8 reverse stock split of its shares.

BeiGene (NASDAQ: BGNE) announced the acceptance of its supplemental biologics license application (sBLA) by the Chinese authority for tislelizumab with chemotherapy to treat metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Endo International plc (NASDAQ: ENDP) announced a commercialization agreement with TLC BioSciences for the rights of TLC599, a treatment in development for osteoarthritis pain. TLC will be responsible for the development of the product and EVL will be responsible for regulatory approval and commercialization in the United States. TLC will receive $30 million upfront and $110 million in milestone payments.

Kiromic BioPharma, Inc. (NASDAQ:KRBP) announced the prioritization of its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT. An investigational new drug (IND) application for Deltacel in combination with a standard antitumor modality is planned for the second half of 2022.

Titan Medical Inc. (NASDAQ: TMDI) announced an agreement with Nissha Medical Technologies for the manufacture of surgical consumables, to be used for verification and validation testing, and pre-clinical and clinical studies of Titan's Enos robotic single access surgical system.

Pre-Market Advancers

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 +1.01  +100%
AKUS
Akouos Inc.
$1.01 +1.01  +100%
QNRX
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
BBI
Brickell Biotech, Inc.
$1.01 +1.01  +100%
AKBA
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
ALNA
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
PRVB
Provention Bio Inc.
$1.01 +1.01  +100%
IVC
Invacare Corporation
$1.01 +1.01  +100%
ENSC
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
BNTC
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

CompanyPriceChange
CADL
Candel Therapeutics Inc.
$1.01 -1.01  -100%
CLVS
Clovis Oncology Inc.
$1.01 -1.01  -100%
ENDP
Endo International plc
$1.01 -1.01  -100%
TYRA
Tyra Biosciences Inc.
$1.01 -1.01  -100%
CTKB
Cytek Biosciences Inc.
$1.01 -1.01  -100%
BLTE
Belite Bio Inc
$1.01 -1.01  -100%
MREO
Mereo BioPharma Group plc
$1.01 -1.01  -100%
CRTX
Cortexyme Inc.
$1.01 -1.01  -100%
PULM
Pulmatrix Inc.
$1.01 -1.01  -100%
RXST
RxSight Inc.
$1.01 -1.01  -100%